Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Pulmonary squamous cell carcinoma has not benefited from improvements in chemotherapy over the past d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	squamous cell carcinoma non-small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy prognostic factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d15dd229062240be89218f46cf0ae8cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d15dd229062240be89218f46cf0ae8cb
record_format	dspace
spelling	oai:doaj.org-article:d15dd229062240be89218f46cf0ae8cb2021-12-02T00:25:24ZOutcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma1179-2728https://doaj.org/article/d15dd229062240be89218f46cf0ae8cb2016-08-01T00:00:00Zhttps://www.dovepress.com/outcomes-and-prognostic-factors-of-chemotherapy-for-patients-with-loca-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Pulmonary squamous cell carcinoma has not benefited from improvements in chemotherapy over the past decade, compared with non-squamous non-small-cell lung cancer. Nowadays, treatment strategies differ between squamous and non-squamous non-small-cell lung cancers. This study aimed to investigate the percentage of patients treated with first-, second-, or third-line chemotherapy and the characteristics of patients for whom chemotherapy has been beneficial. Method: Data on patients with stage IIIB or IV squamous cell carcinoma diagnosed between June 2007 and March 2015, and on patients who had received first-, second-, or third-line chemotherapy between June 2007 and November 2015 at our hospital, were retrospectively extracted from our institutional medical charts. We also compared patients who were treated with chemotherapy (chemotherapy group) and patients who were not (non-chemotherapy group) using multivariate logistic regression and multivariate Cox hazard analyses, respectively. Results: During the study period, 103, 63, and 32 patients received first-, second-, and third-line chemotherapy, respectively. Fifty-one patients did not receive chemotherapy. Factors predicting unlikely chemotherapy included age ≥75 years, Eastern Cooperative Oncology Group (ECOG)-performance status (PS) ≥2, Charlson comorbidity index ≥2, hemoglobin <12.2 g/dL, red cell distribution width ≥13.9%, and serum sodium <140 mEq/L. Factors predicting survival for each line of chemotherapy included the following: ECOG-PS ≥2 for first-line; ECOG-PS ≥2 and lymphocyte count for second-line; and ECOG-PS ≥2, body mass index <18.5 kg/m2, and hemoglobin and lactate dehydrogenase levels for third-line. Conclusion: Approximately 66% of patients received first-line chemotherapy. Of those, 66% and 33% received second- and third-line chemotherapy, respectively. ECOG-PS was always an essential prognostic factor when considering introducing chemotherapy and proceeding with additional chemotherapy. Other markers, such as lymphocyte count, body mass index, anemia, and lactate dehydrogenase level, may be useful depending on the patient and line of chemotherapy. Keywords: squamous cell carcinoma, non-small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, prognostic factorsMinami SOgata YIhara SYamamoto SKomuta KDove Medical Pressarticlesquamous cell carcinomanon-small cell lung cancerfirst-line chemotherapysecond-line chemotherapythird-line chemotherapyprognostic factorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 7, Pp 99-110 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	squamous cell carcinoma non-small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy prognostic factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	squamous cell carcinoma non-small cell lung cancer first-line chemotherapy second-line chemotherapy third-line chemotherapy prognostic factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Minami S Ogata Y Ihara S Yamamoto S Komuta K Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
description	Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Pulmonary squamous cell carcinoma has not benefited from improvements in chemotherapy over the past decade, compared with non-squamous non-small-cell lung cancer. Nowadays, treatment strategies differ between squamous and non-squamous non-small-cell lung cancers. This study aimed to investigate the percentage of patients treated with first-, second-, or third-line chemotherapy and the characteristics of patients for whom chemotherapy has been beneficial. Method: Data on patients with stage IIIB or IV squamous cell carcinoma diagnosed between June 2007 and March 2015, and on patients who had received first-, second-, or third-line chemotherapy between June 2007 and November 2015 at our hospital, were retrospectively extracted from our institutional medical charts. We also compared patients who were treated with chemotherapy (chemotherapy group) and patients who were not (non-chemotherapy group) using multivariate logistic regression and multivariate Cox hazard analyses, respectively. Results: During the study period, 103, 63, and 32 patients received first-, second-, and third-line chemotherapy, respectively. Fifty-one patients did not receive chemotherapy. Factors predicting unlikely chemotherapy included age ≥75 years, Eastern Cooperative Oncology Group (ECOG)-performance status (PS) ≥2, Charlson comorbidity index ≥2, hemoglobin <12.2 g/dL, red cell distribution width ≥13.9%, and serum sodium <140 mEq/L. Factors predicting survival for each line of chemotherapy included the following: ECOG-PS ≥2 for first-line; ECOG-PS ≥2 and lymphocyte count for second-line; and ECOG-PS ≥2, body mass index <18.5 kg/m2, and hemoglobin and lactate dehydrogenase levels for third-line. Conclusion: Approximately 66% of patients received first-line chemotherapy. Of those, 66% and 33% received second- and third-line chemotherapy, respectively. ECOG-PS was always an essential prognostic factor when considering introducing chemotherapy and proceeding with additional chemotherapy. Other markers, such as lymphocyte count, body mass index, anemia, and lactate dehydrogenase level, may be useful depending on the patient and line of chemotherapy. Keywords: squamous cell carcinoma, non-small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, prognostic factors
format	article
author	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_facet	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_sort	Minami S
title	Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
title_short	Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
title_full	Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
title_fullStr	Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
title_full_unstemmed	Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
title_sort	outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/d15dd229062240be89218f46cf0ae8cb
work_keys_str_mv	AT minamis outcomesandprognosticfactorsofchemotherapyforpatientswithlocallyadvancedormetastaticpulmonarysquamouscellcarcinoma AT ogatay outcomesandprognosticfactorsofchemotherapyforpatientswithlocallyadvancedormetastaticpulmonarysquamouscellcarcinoma AT iharas outcomesandprognosticfactorsofchemotherapyforpatientswithlocallyadvancedormetastaticpulmonarysquamouscellcarcinoma AT yamamotos outcomesandprognosticfactorsofchemotherapyforpatientswithlocallyadvancedormetastaticpulmonarysquamouscellcarcinoma AT komutak outcomesandprognosticfactorsofchemotherapyforpatientswithlocallyadvancedormetastaticpulmonarysquamouscellcarcinoma
_version_	1718403769838862336

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma

Ejemplares similares